Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • Toolbox: Coding and Computation
      • Toolbox: Signatures and Cells
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Clinical Trials of Cancer Immunotherapies

Abstract A034: Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma

Manuel Schmidt, Barbara Volz, Kerstin Kapp, Viktor Gruenwald, Matthias Schroff and Burghardt Wittig
Manuel Schmidt
1Mologen AG, Berlin, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barbara Volz
1Mologen AG, Berlin, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kerstin Kapp
1Mologen AG, Berlin, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Viktor Gruenwald
2Medical University Hannover, Hannover, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Matthias Schroff
1Mologen AG, Berlin, Germany,
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Burghardt Wittig
3Foundation Institute Molecular Biology and Bioinformatics, Freie Universitaet, Berlin, Germany.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A034 Published January 2016
  • Article
  • Info & Metrics
Loading
Abstracts: CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY

Abstract

Background: In a first in men, proof-of-principle, multi-center, open-label, single-arm, non-randomized phase 1/2 clinical ASET trial (ClinicalTrials.gov: NCT01265368; EudraCT No.: 2009-016853-16) in patients with advanced RCC the tumor vaccine MGN1601 has shown a good safety profile and improved overall survival in the per-protocol (PP) treated patient population. MGN1601 is a cell-based tumor vaccine consisting of two active pharmaceutical ingredients: Allogeneic (human) cells originating from renal cell carcinoma were gene-modified with four different MIDGE vectors encoding IL-7, GM-CSF, CD80 and CD154. These vaccine cells were combined with the synthetic DNA-based immunomodulator dSLIM®, a potent TLR-9 agonist.

Methods: The tumor vaccine MGN1601 – each dose consists of 107 vaccine cells and 5 mg dSLIM® – was administered 8 times over 12 weeks with 3 weekly and 5 bi-weekly administrations (PP population) in the ASET trial. Specific humoral immune responses in sera from patients before and after treatment with MGN1601 against a natural set of 17 known tumor associated antigens (TAA) expressed by the vaccine cells were evaluated ex-vivo in a translational research program using peptide arrays. On the array each TAA was represented by peptides of 15 amino acids length with an overlap of 13 amino acids.

Results: Nineteen heavily pre-treated patients with advanced RCC have been included into the trial. In the PP population – comprising 10 of these 19 patients – the humoral immune response against TAA expressed on vaccine cells was evaluated. Within each antigen subsets of overlapping peptides were recognized by patient's sera with an abundant or clearly increased intensity after MGN1601 treatment indicating favoured immunogenic regions within a TAA for an individual immune response. Such sets of peptides were identified within each antigen showing individual responses by sera from 2 to eight patients. Remarkably, some of these overlapping peptides were recognized by sera of more than one patient (“shared immunogenic regions”): In particular, 50 to 70 % of treated patients shared response to immunogenic regions within Survivin, Stromelysin, c-Myc, Histone H1.2 and G1/S-specific Cyclin-D1 indicating their comprehensive immunogenic potential. Within other TAA (e.g. p53, telomerase) shared immune responses to peptides were observed at lower rates (20 to 40% of patients), whereas for some of the antigens (e.g. MUC1, Her2/neu) only individual immune responses to the peptides were identified.

Conclusions: The humoral immune response – assessed in patients treated with the tumor vaccine MGN1601 – revealed overlapping peptides within various TAA that induced an immune response shared by up to 7 of 10 patients, indicating comprehensive immunogenic regions within those TAA and their potential use as vaccine epitopes. The specific evaluation of immune response to those TAA remains to further studies.

Citation Format: Manuel Schmidt, Barbara Volz, Kerstin Kapp, Viktor Gruenwald, Matthias Schroff, Burghardt Wittig. Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A034.

  • ©2016 American Association for Cancer Research.
Previous
Back to top
Cancer Immunology Research: 4 (1 Supplement)
January 2016
Volume 4, Issue 1 Supplement
  • Table of Contents

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract A034: Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Abstract A034: Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma
Manuel Schmidt, Barbara Volz, Kerstin Kapp, Viktor Gruenwald, Matthias Schroff and Burghardt Wittig
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A034; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A034

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract A034: Immune responses against tumor associated antigens are induced by treatment with the cell-based tumor vaccine MGN1601 in patients with renal cell carcinoma
Manuel Schmidt, Barbara Volz, Kerstin Kapp, Viktor Gruenwald, Matthias Schroff and Burghardt Wittig
Cancer Immunol Res January 1 2016 (4) (1 Supplement) A034; DOI: 10.1158/2326-6074.CRICIMTEATIAACR15-A034
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Clinical Trials of Cancer Immunotherapies

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies

Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts

  • Abstract A007: Comparison of pretreatment conditioning on efficacy in two cohorts of a pilot study of genetically engineered NY-ESO-1c259T-cells in patients with synovial sarcoma
  • Abstract A010: Personalized neoantigen-targeting vaccines for high-risk melanoma generate epitope spreading
  • Abstract A006: Phase 1 study to evaluate the safety and tolerability of MEDI4736 (durvalumab, durva) + tremelimumab (treme) in patients with advanced solid tumors
Show more Clinical Trials of Cancer Immunotherapies: Poster Presentations - Proffered Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement